Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing

31 January 2022, Durham, UK. 

The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing researcher and entrepreneur David Weinkove, Associate Professor at the Department of Biosciences, Durham University and CEO of Magnitude Biosciences Ltd. 

Dr Weinkove’s appointment comes in a booming era for ageing research, characterised by increasing investment in companies working on therapies to slow ageing. These longevity biotech companies are concentrated in the US but are also found in the UK, as seen with the recently announced Altos Labs, a $3bn organisation with one of its institutes based in Cambridge, England. Through the BSRA, Dr Weinkove wants to make sure that UK researchers are able to play their part in developing therapies that slow biological ageing, which could have a huge impact on healthcare. Ageing is the biggest risk factor for chronic diseases such as Alzheimer’s Disease, which is more and more prevalent as populations age. Slowing ageing may help reduce the onset of these terrible conditions.

David said “I am honoured to be elected Chair of the BSRA and I plan to increase the awareness and influence of the organisation to support UK ageing research. I want to make sure evidence-based research is heard in a field that is increasingly noisy with hype. My experience in both academic and industrial ageing research puts me in a unique position to facilitate meaningful new collaborations between leading innovators.”

David takes over from Prof Claire Stewart of Liverpool John Moores University after 5 years of service to the BSRA.

About the BSRA

The BSRA is a charitable incorporated organisation that was formed in 1939 by researchers studying the biology of ageing. It works to promote and support research on the causes and effects of ageing. It organises an annual conference that brings researchers together from across the world, is engaged in education and outreach, and funds research in the biology of ageing.

About David Weinkove

David Weinkove was appointed as Assistant Professor at Durham University in 2008, after research training in London, the Netherlands and Utah. He was promoted to Associate Professor in 2016. His academic research focuses on ageing in the nematode worm C. elegans. He discovered mutations in bacteria that extend C. elegans lifespan and found a drug that alters bacterial metabolism to slow ageing. His publications have been cited more than 3000 times. In 2018, he co-founded Magnitude Biosciences Ltd, a company that provides research services in C. elegans to companies across the world using unique technology that measures the impact of compounds on ageing, mobility and health. He was a Trustee of the BSRA from 2014 to 2019.

To find out how Magnitude Biosciences can support your research contact us via info@magnitudebiosciences.com 

Press Contact:

Jessica Evans jess@magnitudebiosciences.com

Related Press Releases

Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo:  From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK – July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab service...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK – March 2021 Magnitude Biosciences, a spin-out from Durham University and the leadi...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK – August 2020 Research into new medicines is needed more than ever, but research la...Read More
Magnitude Biosciences’ new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news